
Lyra Therapeutics Inc LYRA.OQ LYRA.O is expected to show a fall in quarterly revenue when it reports results for the period ending June 30 2025
The Watertown Massachusetts-based company is expected to report a 59.5% decrease in revenue to $242 thousand from $598 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lyra Therapeutics Inc is for a loss of 14 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 18.8% in the last three months.
Wall Street's median 12-month price target for Lyra Therapeutics Inc is $2.00, above its last closing price of $0.10.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.15 | -0.14 | -0.12 | Beat | 12.2 |
Dec. 31 2025 | -0.13 | -0.12 | -0.16 | Missed | -33.3 |
Sep. 30 2024 | -0.21 | -0.23 | -0.18 | Beat | 21.1 |
Jun. 30 2024 | -0.33 | -0.33 | -0.74 | Missed | -125.6 |
Mar. 31 2024 | -0.27 | -0.26 | -0.35 | Missed | -33.6 |
Dec. 31 2023 | -0.31 | -0.22 | Beat | 30.2 | |
Sep. 30 2023 | -0.31 | -0.32 | -0.27 | Beat | 15.1 |
Jun. 30 2023 | -0.40 | -0.42 | -0.32 | Beat | 24.4 |
This summary was machine generated May 7 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)